Timely Acquisition Keeps Germany's Dermapharm Growing

With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.

Time is money. Alarm clock and euro banknotes.

Acquiring French dietary supplements specialist Arkopharma Group in January helped Germany’s Dermapharm Holding to post a 10.8% rise in sales to €1.14bn ($1.23bn) in 2023.

The addition of Arkopharma more than offset a drop off in revenues from COVID-19 vaccine production. (Also see "Dermapharm...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

BioGaia Takes Probiotics To Netherlands For First Time

 
• By 

Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.

IQVIA Consumer Health: Digestive Category Driving Global OTC Market Growth

 
• By 

An increasing awareness of and interest in gut health helped the global OTC market grow by 4.6% in value terms in 2024, according to IQVIA Consumer Health.

Dermapharm Seeks To Put Stop To Spanish Slide

 
• By 

Dermapharm shakes up management of Arkopharma subsidiary in Spain with turnaround plan not showing results.

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.

More from Business

Consumers More Often Choosing Private Label First

 

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

People In US Consumer Health News: Bayer North America Treasurer Takes On CFO Role, Too

 

Bayer North America CFO with firm since 2008; Cosette VP for quality, regulatory affairs; FDA labeling review official joins ProPharma; Lifecykel, UFC veterans launch Mongolian training camp; and Beverly Hills surgeons offer skin care supplement.

OLLY’s Lovin’ Libido Claims Score Support With Studies Of Women Reporting ‘Generally Low’ Desire

 

NAD reports the populations of six of seven RCTs Olly referenced as evidence were key in substantiating claims for Lovin’ Libido ashwagandha supplement challenged by Bayer. Supplement industry, though, is challenging the FTC’s RCT standard for claims support.